Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$55.45 USD

55.45
10,808,187

+1.13 (2.08%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $55.46 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market

by Zacks Equity Research

Prothena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial.

Exelixis (EXEL) Gains 30% YTD on Cabometyx, Pipeline Progress

by Zacks Equity Research

Exelixis (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.

The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics

by Zacks Equity Research

Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.

Bristol Myers (BMY) Receives FDA Approval for NSCLC Drug

by Zacks Equity Research

Bristol Myers' (BMY) repotrectinib, a tyrosine kinase inhibitor (???TKI???) targeting ROS1 oncogenic fusions, gets FDA???s approval for NSCLC.

Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA Nod

by Zacks Equity Research

Bristol Myers (BMY) and Vertex (VRTX) drug approvals are in focus in the biotech sector.

Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

Halozyme's (HALO) third-quarter earnings beat estimates, while revenues miss the same. The company maintains revenue guidance for full-year 2023.

Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations

by Zacks Equity Research

Mirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses.

Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More

by Zacks Equity Research

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.

Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike

by Zacks Equity Research

Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.

Exelixis (EXEL) Q3 Earnings and Sales Miss, Annual View Updated

by Zacks Equity Research

Exelixis (EXEL) misses third-quarter 2023 earnings and sales estimates but tightens its annual revenue guidance and increases its R&D guidance.

Pfizer's (PFE) Q3 Loss Narrows, Sales Miss on COVID Slump

by Zacks Equity Research

Pfizer (PFE) reports mixed third-quarter 2023 results. It re-affirms its 2023 sales and earnings guidance provided earlier this month.

Pfizer's (PFE) Key Drugs to Drive Q3 Earnings Amid COVID Decline?

by Zacks Equity Research

Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.

The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical

by Zacks Equity Research

Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical are included in this Analyst Blog.

Bristol-Myers (BMY) Q3 Earnings & Sales Beat, Opdivo Sales Grow

by Zacks Equity Research

Bristol-Myers' (BMY) third-quarter 2023 earnings and sales beat estimates as Opdivo and new products offset losses due to oncology drug Revlimid's generic erosion.

Biotech Stock Roundup: BMY's Q3 Results, PTCT Up on Deal, BEAM's Restructuring News

by Zacks Equity Research

Earnings and other updates from Bristol Myers (BMY) and PTC Therapeutic (PTCT) are in focus in the biotech sector.

Advance GDP Estimate Comes in Higher Than Expectations

by Zacks Equity Research

Advance GDP Estimate Comes in Higher Than Expectations.

Mark Vickery headshot

Q3 GDP +4.9%, Earnings Beats for UPS, Bristol Myers and Honeywell

by Mark Vickery

In the preliminary Q3 GDP print, consumer spending jumped to +4.0% while private domestic investment roared ahead +8.4%.

Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bristol Myers Squibb (BMY) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 13.64% and 0.28%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

META Up +4% on +23% Revenue Growth; IBM and NOW Also Beat

by Mark Vickery

The social media leader posted a big beat on earnings -- $4.39 per share versus expectations of $3.62 and the year-ago number of $1.64 per share.

Ahan Chakraborty headshot

Drug, Biotech Stocks' Q3 Earnings Due on Oct 26: BMY, MRK, BPMC

by Ahan Chakraborty

Let's look at three biotech/drug companies, BMY, MRK and BPMC, slated to release quarterly results on Oct 26.

Earnings Preview: Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Expected to Decline

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Bristol-Myers (BMY) in Q3 Earnings?

by Zacks Equity Research

Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results.

Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals

by Zacks Equity Research

Bristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze technology, meets noninferiority goals in a late-stage kidney cancer study compared with intravenous Opdivo.

Earnings Preview: Bristol Myers Squibb (BMY) Q3 Earnings Expected to Decline

by Zacks Equity Research

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.